迪希德洛克尔塞丁通过调节TREM2激活来缓解多巴胺神经元损失
Rong Yang1, Dai-di Li1, Xiao-Xian Li1
1Key Laboratory of Basic Pharmacology of Ministry of Education and Joint International Research Laboratory of Ethnomedicine of Ministry of Education and Key Laboratory of Basic Pharmacology of Guizhou Province and Laboratory Animal Centre, Zunyi Medical University, Zunyi, Guizhou, China.
概括
在帕金森病中,二甲 (DHQ) 通过激活微质上的TREM2受体来保护多巴胺神经元,减少神经炎症和神经元损失. 这种机制对于DHQ的神经保护作用至关重要.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 帕金森病 (PD) 涉及多巴胺神经元退化和神经炎症.
- 微质介导的神经炎症是PD病变发生的一个关键因素.
- 在骨髓细胞2 (TREM2) 上表达的触发受体是抑制PD中神经炎症的潜在治疗点.
研究的目的:
- 在帕金森病中研究二甲 (DHQ) 的神经保护机制.
- 为了确定DHQ的神经保护是否由微质中的TREM2信号传递中介.
主要方法:
- 使用诱导多巴胺神经元损伤的老鼠模型 (LPS,6-OHDA) 来测试DHQ.
- 使用神经元 (MN9D) 和微质细胞 (BV2) 细胞系来研究TREM2功能.
- 使用TREM2淘汰赛小鼠来确认DHQ的TREM2依赖作用.
主要成果:
- DHQ保护了多巴胺神经元,并抑制了由LPS和6-OHDA引起的神经炎症.
- DHQ激活了微质TREM2信号传递.
- 在TREM2沉默或TREM2淘汰小鼠中,DHQ的神经保护作用和减少炎症性细胞因子被废除.
结论:
- 在帕金森病模型中,DHQ发挥神经保护作用.
- DHQ的机制涉及微质TREM2激活的调节.
相关概念视频
Parkinson's Disease: Treatment
263
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
263
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Parkinson's Disease: Overview
533
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
533
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Alzheimer's Disease: Treatment
181
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Enzyme-linked Receptors
78.2K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
78.2K


